These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 5823074)

  • 21. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
    Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
    Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum antiretinal antibodies (ARA) in patients with choroidal melanoma--preliminary report].
    Kubicka-Trzaska A; Karska-Basta I; Krukierek-Małec K
    Klin Oczna; 2005; 107(10-12):642-5. PubMed ID: 16619809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smooth muscle antibody in malignant disease.
    Whitehouse JM; Holborow EJ; Fairley GH; Alexander P
    Nouv Rev Fr Hematol; 1972; 12(3):383-6. PubMed ID: 4266210
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
    Gogas H; Ioannovich J; Dafni U; Stavropoulou-Giokas C; Frangia K; Tsoutsos D; Panagiotou P; Polyzos A; Papadopoulos O; Stratigos A; Markopoulos C; Bafaloukos D; Pectasides D; Fountzilas G; Kirkwood JM
    N Engl J Med; 2006 Feb; 354(7):709-18. PubMed ID: 16481638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiphospholipid antibodies and melanoma: a link?
    Naldi L; Finazzi G; Brevi A; Cavalieri d'Oro L; Locati F; Marchesi L; Cainelli T; Barbui T
    Dermatology; 1992; 184(2):156. PubMed ID: 1498381
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune studies in malignant melanoma.
    Blake J
    Br J Surg; 1971 Nov; 58(11):856. PubMed ID: 4942024
    [No Abstract]   [Full Text] [Related]  

  • 27. Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNγ-treated autologous melanoma cell vaccine recipients.
    Ravindranath MH; Selvan SR; Terasaki PI
    J Immunotoxicol; 2012; 9(3):282-91. PubMed ID: 22283601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunological aspects in malignant melanoma].
    Macher E
    Arch Dermatol Forsch; 1972; 244():234-9. PubMed ID: 4675197
    [No Abstract]   [Full Text] [Related]  

  • 30. Host factors in human malignant melanoma.
    Lewis MG
    Pathol Annu; 1971; 6():171-95. PubMed ID: 4949366
    [No Abstract]   [Full Text] [Related]  

  • 31. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific tissue and tumor responses of chimpanzees following immunization against human melanoma.
    Hornung MO; Krementz ET
    Surgery; 1974 Apr; 75(4):477-86. PubMed ID: 4131002
    [No Abstract]   [Full Text] [Related]  

  • 33. The cell-mediated immunity in patients with malignant melanoma.
    Fixa B; Komárková O; Kraus Z; Simková H
    Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunology of malignant melanoma].
    Misgeld V
    Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
    [No Abstract]   [Full Text] [Related]  

  • 35. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen.
    Burlingame RW; Rubin RL; Balderas RS; Theofilopoulos AN
    J Clin Invest; 1993 Apr; 91(4):1687-96. PubMed ID: 8473512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Basis for a specific-active immunotherapy in malignant melanoma].
    Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The immunology of malignant melanoma (author's transl)].
    Schieferstein G
    Klin Wochenschr; 1978 Mar; 53(16):241-53. PubMed ID: 355711
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 39. [Endolymphatic radionuclide adjuvant therapy of melanoma and its side effects on the cellular immune system].
    Richter G; Heidenbluth I; Heidelbach U
    Dermatol Monatsschr; 1982 Dec; 168(12):797-806. PubMed ID: 7169101
    [No Abstract]   [Full Text] [Related]  

  • 40. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients.
    Kölmel KF; Grange JM; Krone B; Mastrangelo G; Rossi CR; Henz BM; Seebacher C; Botev IN; Niin M; Lambert D; Shafir R; Kokoschka EM; Kleeberg UR; Gefeller O; Pfahlberg A
    Eur J Cancer; 2005 Jan; 41(1):118-25. PubMed ID: 15617996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.